Subscribe To
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) […] The post Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO A...
Read More
Posted: Apr 26 2023, 22:41
Author Name: forextv
Views: 081936